Driving Innovation To Solve The Challenges In Treating Cancer
An estimated 1.1 million people worldwide were diagnosed with a type of blood cancer in 2018, accounting for seven percent of all cancer diagnosed.[I] Blood cancer is an umbrella term for all cancers that affect the blood, the bone marrow or the lymphatic system. The three main types of blood cancers include leukemia, lymphoma and myeloma.[ii] Scientific advancements have brought new treatment options that can improve outcomes to patients. AbbVie is at the forefront of these advancements, leading the transformation of care for patients with blood cancer. By combining deep knowledge in key areas of biology with cutting-edge research technologies, AbbVie is driving innovation for patients with difficult-to-treat diseases. Our team of experts and world-class scientists are leading the way in the research of targeted medicines – therapies that directly attack the means by which a cancer cell grows and replicates. All cells, including cancer cells undergo a natural, controlled process known as apoptosis or cell death. In some blood cancers, a protein called BCL-2 builds up and prevents cancer cells from undergoing their natural process of regulated cell death.[iii] In addition, an enzyme called Bruton’s tyrosine kinase, or BTK, is abnormally activated in some blood cancers, causing B cells (white blood cells whose primary role is to produce antibodies) to grow uncontrollably and crowd out normal cells.[iv] Our deep understanding of apoptosis and B-cell signaling allows us to identify ways to restore cancer cells’ ability to die or block their reproduction to develop potential treatments for people living with cancer. The United Nations’ Sustainable Development Goal 3 is to ensure healthy lives and promote well-being for all at all ages. AbbVie researches and develops medicines for difficult-to-treat diseases like blood cancer where we can leverage our expertise for the benefit of patients and contribute to the scientific body of knowledge. Sustainable Development Goal 17 is to strengthen the means of implementation and revitalize the global partnership for sustainable development. Specifically, Goal 17 encourages and promotes effective public, private and government partnerships. At AbbVie, we believe the best and fastest way to deliver breakthrough medicines for patients with cancer is through collaborations that bring together the brightest minds in oncology. Our dedicated and experienced team joins forces with innovative partners that complement our strengths, capabilities and commitment to oncology. [i]World Cancer Research Fund (2019). Worldwide cancer data. https://www.wcrf.org/dietandcancer/cancer-trends/worldwide-cancer-data [ii]American Society of Hematology (2019). Blood Cancers. https://www.hematology.org/Patients/Cancers/ [iii]Letai, AG (2008). Diagnosing and exploiting cancer’s addiction to blocks in apoptosis. Nat Rev Cancer. 8(2). [iv]Pal Singh S, et al. (2018). Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer.